Lisnr named one of TEN startups outside Silicon Valley to watch

Lisnr, a Serra Capital II company, was recently named to VentureBeat's "10 Startups Outside Silicon Valley to Watch in 2018" list. Criteria for the list included influx of venture capital, new promising hires, and agreements or partnerships with a large new customers.

Lisnr develops ultrasonic audio technology that uses inaudible Smart Tones to transmit information. 

Source: https://venturebeat.com/2018/01/02/10-startups-outside-silicon-valley-to-watch-in-2018/

Label Insight Has Exciting Press in December

Label Insight, a Serra Capital II portfolio company, had an exciting month of December as it first announced a partnership with 1WorldSync, and also announced the raise of $21 million in new investments. 

1WorldSync is the leading provider of product content solutions, and the partnership will help create the industry's most comprehensive solution for product data distribution and transparency. 

Label Insight uses data science to bring transparency to food product labels to help people with allergies and dietary restrictions know exactly what they’re putting in their body. Label Insight has now raised more than $35 million to date. The company says it will use the funding to hire more data scientists and continue product development.

Source: https://www.americaninno.com/chicago/funding-chicago/label-insight-raises-21m-to-tell-you-more-about-whats-in-your-food/

Personalized Cancer Medicine Research Spearheaded by CureMatch Co-Founders

CureMatch, a Serra Capital III portfolio company, has recently had a study published in the International Computational Intelligence Book. Co-Founders Igor F. Tsigelny, Ph.D. and Razelle Kurzrock, M.D. along with colleagues from UC San Diego and University of Bergen have authored a personalized cancer medicine study examining activation of protein complexes utilizing an innovative 4D approach.

CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS, and is considered by many to be the future of cancer treatment. CureMatch’s decision support system guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient’s own tumor.

Dr. Igor Tsigelny says, "Until now, only static information of mutations has been used to predict functional changes of proteins. We propose to move to the next level and add flexibility criteria for a 4D approach."

Source: https://www.prnewswire.com/news-releases/personalized-cancer-medicine-research-spearheaded-by-curematch-co-founders-300568227.html

Spatial Featured in Disruptor Daily

Spatial, a Serra Capital III portfolio company, was recently featured on Disruptor Daily in an article  titled "Spatial.ia: Personalizing Automotive Rides Through the Use of Fast Moving Social Data." The article further interviewed CEO and Founder of Spatial, Lyden Foust, on the history of the company, how it solves current problems and the future of Spatial.

Spatial combines machine-assisted analysis and human-driven data like social media content to provide a cultural map of cities.  Spatial's cultural overlays make maps more useful for many industries including automobile navigation, real estate, apartment search, vacation rental and many more.

Source: https://www.disruptordaily.com/spatial-ai-personalizing-automotive-rides-use-fast-moving-social-data/

Clarify Medical Announces National Launch of Home Light Therapy System for Psoriasis

Clarify Medical, a Serra Capital III portfolio company, recently announced the launch of its commercial product, the Home Light Therapy System. This FDA-cleared, home-based treatment technology for psoriasis and vitiligo is now rolling out for national distribution. 

Clarify brings handheld, guided therapy to millions of patients, while staying wirelessly connected to physicians and dermatologists. Clarify Medical improves care by bringing convenient, low-cost therapy into a patient’s home.

Source: http://www.businesswire.com/news/home/20171114006286/en/Clarify-Medical-Announces-National-Launch-Home-Light

Paystand Secures $6M Series A Funding

Paystand, a Serra Capital II portfolio company, announced in November a $6M Series A funding round. BlueRun Ventures led the round, with participation from Serra Ventures.

Paystand is a next generation payment & eCommerce checkout system that enables any organization to receive money in their website, social network, or web application without transaction costs. They are the first multi-payment gateway that accepts credit cards (Visa/MasterCard/Amex/Discover), eCheck (ACH/Dwolla), and eCash (Bitcoins) with 0% transaction fees.

The money raised will be utilized by scaling its accounts receivable systems and launch a new free accounts payable product line.

Source: https://www.businesswire.com/news/home/20171115006571/en/PayStand-Secures-6M-Series-Funding-Disrupt-B2B

LISNR Announces Partnership with Synchrony Financial; Selected As CES 2018 Innovation Awards Honoree

Lisnr, a Serra Capital II portfolio company, has made some exciting announcements in the month of November.  LISNR announced it has secured a strategic investment from Synchrony Financial, a premier consumer financial services company. Additionally, LISNR shared that it has been selected as a CES 2018 Innovation Awards Honoree in the Software and Mobile Apps category for the second year in a row. The CES Innovation Awards is an annual competition honoring outstanding design and engineering in consumer technology products.

LISNR is the leading global provider of data-over-audio technology, a high frequency, inaudible Smart Tone technology; a new communication protocol that sends data over audio.

Source: http://lisnr.com/portfolio-items/lisnr-secures-strategic-investment-from-synchrony-financial/

Source: http://www.ces.tech/Events-Experiences/Innovation-Awards-Program/Honorees.aspx

Inprentus Partners with NASA

Inprentus, a Serra Capital II portfolio company, has announced that it has partnered with NASA Goddard Space Flight Center. Inprentus manufactures blazed diffraction gratings for x-ray and extreme ultraviolet light (EUV).

Through its Heliophysics Technology and Instrument Development for Science, or H-TIDeS, program, Inprentus will provide mechanically ruled, high line density, ultra-low micro roughness, blazed gratings to observe extreme ultraviolet (EUV) radiation environments such as the solar corona. Inprentus will provide four iterations of diffraction gratings for evaluation.

Source: http://www.prweb.com/releases/2017/10/prweb14836277.htm

Chicago Bears’ Prince Amukamara Invests In Opendorse

Opendorse, a Serra Capital III portfolio company, has received an investment from Bears player Prince Amukamara, who is participating in the company's $3.5M Series A financing round. More than a third of the financing is coming from Amukamara and former Husker football players.

Opendorse connects marketers with athletes to secure sponsored social media activations from the world's most influential athletes. The company was co-founded back in 2013 by Amukamara’s ex-teammates — Blake Lawrence and Adi Kunalic.

Source: https://www.sporttechie.com/chicago-bears-prince-amukamara-invests-opendorse/

New Patent Issued to Nanomedical Diagnostics

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced a new patent issued to the company on Oct 17. The new patent is for the use of graphene biosensors with DNA probes to identify DNA sequences for precision medicine, and will enable the company’s technology to bring the benefits of lower costs, easier process, and higher throughput to the world of liquid biopsy and other DNA detection applications.

Nanomed is a life science company that has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive real-time direct detection of biomolecules. As the world’s only mass-manufacturer of graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.

Source: http://www.prweb.com/releases/nanomedical_diagnostics/dna_probe_patent_issued/prweb14810978.htm

Chris Crocker Joins HomeBay

HomeBay, a Serra Capital III portfolio company, announced on Oct. 24 that it has welcomed Chris Crocker to the team. Crocker is the former VP of Strategic Partnerships at Zillow, as well as the former Chief Operating Office at Pacific Sotheby's, and brings more than 20 years' experience to the HomeBay team.

HomeBay helps sellers to navigate the real estate process via automated & live help to make the listing, selling and closing processes faster, easier and less stressful. The company also puts homes in front of millions of buyers by syndicating the listings to the MLS and the most popular real estate sites across the web.

"We're thrilled for Chris to join the Home Bay team. We've admired Chris for his leadership as well as his perspective and approach in advocating and leveraging technology to help partners," said Home Bay co-founder Tom Owen. "We place tremendous value on fostering great partnerships and building innovative products that support our partners. Chris is the right choice to lead this critical role."

Source: https://www.prnewswire.com/news-releases/former-vp-of-partnerships-at-zillow-and-former-coo-of-pacific-sothebys-joins-home-bay-technologies-inc-300533603.html

Clarify Medical Announces Partnership With DermatologistOnCall

Clarify Medical, a Serra Capital III portfolio company, has partnered with DermatologistOnCall to to Innovate the Treatment of Chronic Skin Conditions. Clarify Medical  is a connected device that uses cutting edge LED technology to bring personal, private prescription phototherapy to patients with psoriasis, eczema and vitiligo.

“We are delighted to be working with DermatologistOnCall,” said Charlene Kakimoto MD, Clarify Medical’s Chief Medical Officer. “More than 25 percent of the patients we’ve engaged with do not have a dermatologist, and have asked for our help in finding one. DermatologistOnCall will provide an ideal response for this ongoing need, especially in areas of the country where office visits involve long wait or travel times. Together we have a fantastic opportunity to improve care for appropriate patients with chronic skin conditions. Our Clarify CarePartners, through the Clarify App, will help make sure that busy practices are diagnosing patients and managing their care, not dealing with questions about home phototherapy.”

HomeBay Brings Florida Home Sellers and Buyers Significant Costs Savings

HomeBay, a Serra Capital III portfolio company, has expanded to Florida. Home Bay offers consumers a new way to buy and sell homes without commission fees, saving its customers an average of $16,000 per transaction. HomeBay is a technology driven real estate company that helps sellers to navigate the real estate process via automated & live help to make the listing, selling and closing processes faster, easier and less stressful.

"Consumers using traditional agents are a very dissatisfied group. Even when consumers like the agent, they understandably hate the fees. Intuitively, consumers understand that three to six percent of the price of their home is way too much.," said Tom Owen, co-founder of HomeBay. "Based on our strong adoption and success, we believe consumers are eager for a superior solution at a fraction of the cost."

Source: https://www.prnewswire.com/news-releases/home-bay-technologies-brings-florida-home-sellers-and-buyers-significant-costs-savings-with-a-no-commission-fee-model-300533576.html

Inprentus to Supply Shanghai Synchrotron Radiation Facility

Inprentus, a Serra Capital II portfolio company, has been awarded a contract to supply the Shanghai Synchrotron Radiation Facility (SSRF) with three custom designed blazed diffraction gratings for use at beamlines within SSRF. Inprentus designs, manufactures and sells X-ray and EUV diffraction gratings for synchrotron radiation facilities that are used for a variety of scientific and commercial applications by many Fortune 500 companies, academic institutions and government laboratories around the world.

Ron van Os, CEO of Inprentus, commented, "Market demand is growing for Inprentus diffraction grating products throughout Asia. With this win at SSRF, Inprentus has shown that its advanced specifications and custom design capabilities are a winning combination in the synchrotron market."

Source: https://www.prnewswire.com/news-releases/inprentus-to-supply-shanghai-synchrotron-radiation-facility-with-x-ray-diffraction-gratings-300531225.html

ANDalyze Demonstrated its Water Quality Measurement Technology at WATEC

ANDalyze, a Serra Capital I portfolio company, demonstrated its water quality measurement technology at the Water Technology and Environmental Control (WATEC) Conference in Tel Aviv, Israel in September. 

ANDalyze has developed a superior methodology for detecting and quantifying analyte levels based on the discovery of the catalytic property of DNA (DNAzymes). This biosensor technology is a universal platform that offers a simple, fast, inexpensive, and reliable detection of trace metals and other analytes.

Source: http://www.prweb.com/releases/2017/09/prweb14712174.htm

 

Asto Ct's scanner could be lifesaver for horses

Asto CT, a Serra Capital III portfolio company, was recently featured in the Wisconsin State Journal. The Asto CT Equina™ offers a paradigm shift in equine x-ray CT imaging by providing rapid 3D imaging of the lower limbs and head without subjecting the horses to general anesthesia.  With its high-precision robotic technology, the Equina™ is capable of safely imaging the lower limbs under load, as well as the head and neck of the standing horse in a single series.

Fractures for horses can be deadly and hard to detect. Often it happens that by the time the broken bone is detected, it is too late and the horse must be put down. Asto CT is trying to change this with their revolutionary scanner. It indeed will be a lifesaver for horses if the company is successful. 

Source: http://host.madison.com/wsj/business/technology/ct-scanner-could-be-lifesaver-for-horses/article_3fe515f1-88ba-5b1b-8e03-c8ba5b788abd.html

Spatial a finalist for BMW startup challenge

Spatial, a Serra Capital III portfolio company, was announced on September 20 as a finalist in the BMW Startup Challenge. Spatial combines machine-assisted analysis and human-driven data like social media content to provide a cultural map of cities.  Spatial's cultural overlays make maps more useful for many industries including automobile navigation, real estate, apartment search, vacation rental and many more.

Spatial is one of two US companies selected, and each finalist will present their technologies to a jury of leading innovators in the startup world. The top three startups, selected from those 10 finalists, will then be invited to present their innovations to a live audience consisting of international journalists and entrepreneurs in a special BMW Startup Symposium in Amsterdam on September 26th.

Source: https://medium.com/spatial-ai/spatial-announced-as-finalist-for-bmw-startup-challenge-7763d30b5ac2

Ringr Featured on Shoutmeloud.com

Ringr, a Serra Capital II portfolio company, was featured on shoutmeloud.com on September 15. Ringr offers a free and premium software application which allows users to record studio-quality audio interviews. The technology eliminates staticky phone calls on the radio or warbly internet audio on podcasts. The Ringr technology changes the whole interview experience.

The article showcases how with Ringr, you can record a podcast Interview with a guest using nothing but a smartphone. 

Source: https://www.shoutmeloud.com/ringr-review.html

Nanomedical Diagnostics' Agile R100 Detects Zika

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a new publication in Biosensors and Bioelectronics demonstrating detection of Zika viral antigen using their label-free Agile R100 biosensor.  Nano is a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development.

The Zika virus, a mosquito-borne infection, has been shown to be a cause of microcephaly and other severe fetal brain defects. For pregnant women, it is especially important to reliably identify Zika virus infection in a timely manner, but current methods show high false positive rates and can take weeks to return test results. The compact and portable Agile R100 represents a potential methodology to identify Zika infection promptly.

Curematch Co-founders Study the molecular Alterations of Genes to Develop Personalized Cancer Therapy Options

CureMatch, a Serra Capital III portfolio company, has recently published a study in the journal of Cancer Biology & Therapy. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

The study conducted by CureMatch highlighted the role of a specific molecular mutation in eosinophilic cystitis, and how their methods might better treat this type of condition. 

Source: http://www.prnewswire.com/news-releases/curematch-co-founders-study-the-molecular-alterations-of-genes-to-develop-personalized-cancer-therapy-options-300516362.html